These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 36617366)

  • 41. Population Pharmacokinetics Study of Contezolid (MRX-I), a Novel Oxazolidinone Antibacterial Agent, in Chinese Patients.
    Li L; Wu H; Chen Y; Yuan H; Wu J; Wu X; Zhang Y; Cao G; Guo B; Wu J; Zhao M; Zhang J
    Clin Ther; 2020 May; 42(5):818-829. PubMed ID: 32389326
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A pharmacometric case study regarding the sensitivity of structural model parameter estimation to error in patient reported dosing times.
    Knights J; Rohatagi S
    J Pharmacokinet Pharmacodyn; 2015 Dec; 42(6):627-37. PubMed ID: 26209956
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Non-compartment model to compartment model pharmacokinetics transformation meta-analysis--a multivariate nonlinear mixed model.
    Wang Z; Kim S; Quinney SK; Zhou J; Li L
    BMC Syst Biol; 2010 May; 4 Suppl 1(Suppl 1):S8. PubMed ID: 20522258
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Population pharmacokinetics of the selective serotonin 5-HT1A receptor partial agonist piclozotan.
    Mondick JT; Oo C; Patel D; Fujitani T; Shimizu K; Barrett JS
    Am J Ther; 2009; 16(2):106-15. PubMed ID: 19300037
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Handling Missing Dosing History in Population Pharmacokinetic Modeling: An Extension to MDM Method.
    Wang Y; Liu X
    CPT Pharmacometrics Syst Pharmacol; 2019 Jan; 8(1):39-49. PubMed ID: 30536631
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Simultaneous vs. sequential analysis for population PK/PD data I: best-case performance.
    Zhang L; Beal SL; Sheiner LB
    J Pharmacokinet Pharmacodyn; 2003 Dec; 30(6):387-404. PubMed ID: 15000421
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Predicting Antibiotic Effect of Vancomycin Using Pharmacokinetic/Pharmacodynamic Modeling and Simulation: Dense Sampling versus Sparse Sampling.
    Kim YK; Lee JH; Jang HJ; Zang DY; Lee DH
    Antibiotics (Basel); 2022 May; 11(6):. PubMed ID: 35740150
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Two Innovative Approaches to Optimize Vancomycin Dosing Using Estimated AUC after First Dose: Validation Using Data Generated from Population PK Model Coupled with Monte-Carlo Simulation and Comparison with the First-Order PK Equation Approach.
    Liu Q; Huang H; Xu B; Li D; Liu M; Shaik IH; Wu X
    Pharmaceutics; 2022 May; 14(5):. PubMed ID: 35631590
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacokinetics and pharmacodynamics of intravenous dexmedetomidine in healthy Korean subjects.
    Lee S; Kim BH; Lim K; Stalker D; Wisemandle W; Shin SG; Jang IJ; Yu KS
    J Clin Pharm Ther; 2012 Dec; 37(6):698-703. PubMed ID: 22650799
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Population Pharmacokinetics of Lithium Carbonate in Young Male Healthy Chinese Volunteers.
    Yu W; Sun X; Li Y; Li M; Wang K; Li H
    Pharmacopsychiatry; 2016 Sep; 49(5):177-181. PubMed ID: 27124003
    [No Abstract]   [Full Text] [Related]  

  • 51. Evaluation of bootstrap methods for estimating uncertainty of parameters in nonlinear mixed-effects models: a simulation study in population pharmacokinetics.
    Thai HT; Mentré F; Holford NH; Veyrat-Follet C; Comets E
    J Pharmacokinet Pharmacodyn; 2014 Feb; 41(1):15-33. PubMed ID: 24317870
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Population pharmacokinetics of moxifloxacin and its concentration-QT interval relationship modeling in Chinese healthy volunteers.
    Xu FY; Huang JH; He YC; Liang LY; Li LJ; Yang J; Yin F; Xu L; Zheng QS; Wang K
    Acta Pharmacol Sin; 2017 Nov; 38(11):1580-1588. PubMed ID: 28713157
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A population pharmacokinetic meta-analysis of custirsen, an antisense oligonucleotide, in oncology patients and healthy subjects.
    Edwards AY; Elgart A; Farrell C; Barnett-Griness O; Rabinovich-Guilatt L; Spiegelstein O
    Br J Clin Pharmacol; 2017 Sep; 83(9):1932-1943. PubMed ID: 28294391
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Mixed Effects Modeling Using Stochastic Differential Equations: Illustrated by Pharmacokinetic Data of Nicotinic Acid in Obese Zucker Rats.
    Leander J; Almquist J; Ahlström C; Gabrielsson J; Jirstrand M
    AAPS J; 2015 May; 17(3):586-96. PubMed ID: 25693487
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Population pharmacokinetics of metronidazole evaluated using scavenged samples from preterm infants.
    Cohen-Wolkowiez M; Ouellet D; Smith PB; James LP; Ross A; Sullivan JE; Walsh MC; Zadell A; Newman N; White NR; Kashuba AD; Benjamin DK
    Antimicrob Agents Chemother; 2012 Apr; 56(4):1828-37. PubMed ID: 22252819
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Simulating realistic patient profiles from pharmacokinetic models by a machine learning postprocessing correction of residual variability.
    Kaikousidis C; Bies RR; Dokoumetzidis A
    CPT Pharmacometrics Syst Pharmacol; 2024 Jun; ():. PubMed ID: 38877660
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficient strategy for obtaining reliable pharmacokinetic parameters in population compartmental approaches.
    Lee J; Kang D; Kim E; Kim BH
    Int J Clin Pharmacol Ther; 2016 Jan; 54(1):11-8. PubMed ID: 26521928
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Non linear mixed effects analysis in PET PK-receptor occupancy studies.
    Berges A; Cunningham VJ; Gunn RN; Zamuner S
    Neuroimage; 2013 Aug; 76():155-66. PubMed ID: 23518008
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Midazolam Single Time Point Concentrations to Estimate Exposure and Cytochrome P450 (CYP) 3A Constitutive Activity Utilizing Limited Sampling Strategy With a Population Pharmacokinetic Approach.
    Yang J; Patel M; Nikanjam M; Capparelli EV; Tsunoda SM; Greenberg HE; Penzak SR; Aubrey Stoch S; Bertino JS; Nafziger AN; Ma JD
    J Clin Pharmacol; 2018 Sep; 58(9):1205-1213. PubMed ID: 29663428
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pharmacometrics: modelling and simulation tools to improve decision making in clinical drug development.
    Gieschke R; Steimer JL
    Eur J Drug Metab Pharmacokinet; 2000; 25(1):49-58. PubMed ID: 11032091
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.